Vertex Pharmaceuticals financials
$526.73−0.18%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.33B | $2.99B | $3.19B | $3.08B | $2.96B | $2.77B | $2.91B | $2.77B | $2.65B | $2.69B | $2.52B | $2.48B |
| Gross profit | $2.84B | $2.59B | $2.72B | $2.66B | $2.56B | $2.41B | $2.49B | $2.38B | $2.27B | $2.35B | $2.15B | $2.16B |
| Gross margin | 85.3% | 86.8% | 85.4% | 86.5% | 86.3% | 86.9% | 85.5% | 85.8% | 85.9% | 87.3% | 85.4% | 87.2% |
| Operating income | $1.25B | $1.14B | $1.21B | $1.19B | $1.15B | $630.1M | $1.03B | $1.12B | -$3.51B | $1.14B | $988.5M | $1.04B |
| Net income | $1.10B | $1.03B | $1.19B | $1.08B | $1.03B | $646.3M | $913.0M | $1.05B | -$3.59B | $1.10B | $968.8M | $1.04B |
| Net margin | 33.0% | 34.5% | 37.3% | 35.2% | 34.8% | 23.3% | 31.4% | 37.7% | −135.8% | 40.9% | 38.5% | 41.7% |
| Diluted EPS | $4.31 | $4.02 | $4.65 | $4.20 | $3.99 | $2.49 | $3.63 | $4.01 | $-13.92 | $4.21 | $3.72 | $3.97 |
| EBITDA | $1.32B | $1.19B | $1.32B | $1.29B | $1.21B | $1.08B | $1.16B | $1.18B | $988.4M | $1.27B | $956.0M | $1.13B |
| Operating cash flow | $1.13B | $1.43B | $498.0M | $1.24B | $1.07B | $818.9M | $584.6M | $1.37B | -$3.75B | $1.31B | $233.3M | $1.27B |
| Free cash flow | $1.01B | $1.29B | $348.6M | $1.14B | $927.4M | $778.2M | $492.0M | $1.30B | -$3.82B | $1.24B | $175.2M | $1.23B |
| Diluted shares | 255.2M | 256.3M | 256.0M | 257.6M | 258.9M | 259.5M | 251.4M | 261.0M | 258.1M | 261.1M | 260.7M | 260.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.14B | $5.49B | $5.08B | $4.94B | $4.97B | $4.67B |
| Short-term investments | $1.71B | $1.75B | $1.52B | $1.35B | $1.41B | $1.53B |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $111.4M |
| Total assets | $27.42B | $26.48B | $25.64B | $24.86B | $24.04B | $22.88B |
| Total liabilities | $7.18B | $7.12B | $6.98B | $7.54B | $6.86B | $6.38B |
| Shareholders' equity | $20.25B | $19.36B | $18.67B | $17.32B | $17.18B | $16.50B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology